Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning
Update: 2025-12-04
Description
Featuring an interview with Dr Matthew Lunning, including the following topics:
- Reflection on the advances made in chimeric antigen receptor (CAR) T-cell therapy (0:00 )
- Overview of the CAR T-cell therapy administration process (4:40 )
- Opportunities for referral for CAR T-cell therapy (10:05 )
- Selection of a CAR T-cell therapy based on patient characteristics (16:09 )
- Sequencing of CAR T-cell therapy for various non-Hodgkin lymphomas (23:23 )
- Safety regulations and mitigation strategies for adverse events (30:36 )
- Case: A woman in her early 80s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives lisocabtagene maraleucel (36:16 )
- Case: A man in his early 60s with R/R mantle cell lymphoma receives brexucabtagene autoleucel (43:09 )
- Case: A man in his early 60s with R/R multiple myeloma receives ciltacabtagene autoleucel (49:09 )
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
